Dosing & Uses
Dosage Forms & Strengths
tablet
- 25mg
- 50mg
- 100mg
- 150mg
Depression
Initiate at low dose (25 mg q8-12hr) and gradually titrate upward every 5-7 days up to 200-300 mg PO qHS
If dose exceeds 300 mg/day, administer in divided doses q12hr
Outpatient: Not to exceed 400 mg/day
Inpatient: May require higher doses, up to 600 mg/day divided q12hr
Not recommended
Use caution; avoid use
Depression
Initiate at low dose (25 mg q8-12hr) and gradually titrate upward every 5-7 days up to 200-300 mg PO qHS
If dose exceeds 300 mg/day, administer in divided doses q12hr
Outpatient: Not to exceed 400 mg/day
Inpatient: May require higher doses, up to 600 mg/day divided q12hr
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (17)
- disopyramide
amoxapine and disopyramide both increase QTc interval. Contraindicated.
- ibutilide
amoxapine and ibutilide both increase QTc interval. Contraindicated.
- indapamide
amoxapine and indapamide both increase QTc interval. Contraindicated.
- iobenguane I 123
amoxapine decreases effects of iobenguane I 123 by pharmacodynamic antagonism. Contraindicated. If clinically appropriate, discontinue drugs that decrease uptake of NE for at least 5 half-lives; may cause false-negative imaging results.
- isocarboxazid
isocarboxazid and amoxapine both increase serotonin levels. Contraindicated.
- linezolid
linezolid and amoxapine both increase serotonin levels. Contraindicated.
- pentamidine
amoxapine and pentamidine both increase QTc interval. Contraindicated.
- phenelzine
phenelzine and amoxapine both increase serotonin levels. Contraindicated.
- pimozide
amoxapine and pimozide both increase QTc interval. Contraindicated.
- procainamide
amoxapine and procainamide both increase QTc interval. Contraindicated.
- procarbazine
procarbazine and amoxapine both increase serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use.
- quinidine
quinidine and amoxapine both increase QTc interval. Contraindicated.
- safinamide
amoxapine, safinamide. Either increases toxicity of the other by serotonin levels. Contraindicated. Concomitant use could result in life-threatening serotonin syndrome.
- selegiline
selegiline and amoxapine both increase serotonin levels. Contraindicated. Concurrent use or use within 14 days of selegiline treatment is contraindicated
- sotalol
amoxapine and sotalol both increase QTc interval. Contraindicated.
- tranylcypromine
tranylcypromine and amoxapine both increase serotonin levels. Contraindicated.
- ziprasidone
ziprasidone and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Contraindicated.
Serious - Use Alternative (134)
- adagrasib
adagrasib, amoxapine. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.
- albuterol
amoxapine, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- amiodarone
amoxapine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.
- amitriptyline
amitriptyline and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
amitriptyline and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug. - arformoterol
amoxapine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- arsenic trioxide
amoxapine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.
- artemether
artemether and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- artemether/lumefantrine
amoxapine and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.
- benzphetamine
amoxapine, benzphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- buprenorphine
buprenorphine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine buccal
buprenorphine buccal and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine subdermal implant
buprenorphine subdermal implant and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine transdermal
buprenorphine transdermal and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- buspirone
amoxapine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- calcium/magnesium/potassium/sodium oxybates
amoxapine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- chlorpromazine
chlorpromazine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- citalopram
citalopram and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.
- clarithromycin
amoxapine and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug.
- clomipramine
amoxapine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug. - clonidine
amoxapine decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.
- cyclobenzaprine
amoxapine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- dacomitinib
dacomitinib will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities.
- desipramine
amoxapine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. - desvenlafaxine
amoxapine and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.
- dexfenfluramine
amoxapine, dexfenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dexmethylphenidate
amoxapine, dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dextroamphetamine
amoxapine, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dextromethorphan
amoxapine and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug.
- diethylpropion
amoxapine, diethylpropion. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dobutamine
amoxapine, dobutamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dofetilide
amoxapine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.
- dolasetron
dolasetron, amoxapine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
- donepezil
donepezil and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- dopamine
amoxapine, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dopexamine
amoxapine, dopexamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dosulepin
amoxapine and dosulepin both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and dosulepin both increase serotonin levels. Avoid or Use Alternate Drug. - doxepin
amoxapine and doxepin both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and doxepin both increase serotonin levels. Avoid or Use Alternate Drug. - dronedarone
amoxapine and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.
- droperidol
amoxapine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- duloxetine
duloxetine and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
- ephedrine
amoxapine, ephedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- epinephrine
epinephrine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine, epinephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. - epinephrine racemic
epinephrine racemic and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine, epinephrine racemic. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. - erythromycin base
amoxapine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin ethylsuccinate
amoxapine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin lactobionate
amoxapine and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin stearate
amoxapine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.
- escitalopram
escitalopram and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
- fenfluramine
amoxapine, fenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- fexinidazole
fexinidazole and amoxapine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.
- fluconazole
amoxapine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.
- fluoxetine
fluoxetine and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
- fluphenazine
fluphenazine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- fluvoxamine
fluvoxamine and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
- formoterol
amoxapine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. - fosamprenavir
fosamprenavir increases levels of amoxapine by decreasing metabolism. Avoid or Use Alternate Drug.
- givosiran
givosiran will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.
- granisetron
granisetron, amoxapine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
- guanfacine
amoxapine decreases effects of guanfacine by Other (see comment). Avoid or Use Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.
- haloperidol
amoxapine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.
- hydroxychloroquine sulfate
hydroxychloroquine sulfate and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- imipramine
amoxapine and imipramine both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and imipramine both increase serotonin levels. Avoid or Use Alternate Drug. - iobenguane I 131
amoxapine will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.
- isoproterenol
amoxapine, isoproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- ivosidenib
ivosidenib and amoxapine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.
- ketoconazole
amoxapine and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.
- levalbuterol
amoxapine, levalbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- levoketoconazole
amoxapine and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.
- levomilnacipran
levomilnacipran and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
- lisdexamfetamine
amoxapine, lisdexamfetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- lofepramine
amoxapine and lofepramine both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and lofepramine both increase serotonin levels. Avoid or Use Alternate Drug. - lumefantrine
amoxapine and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.
- macimorelin
macimorelin and amoxapine both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.
- maprotiline
amoxapine and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug. - mefloquine
mefloquine increases toxicity of amoxapine by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.
- meperidine
amoxapine and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.
- metaproterenol
amoxapine, metaproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- methamphetamine
amoxapine, methamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- methylene blue
amoxapine and methylene blue both increase serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.
- methylenedioxymethamphetamine
amoxapine, methylenedioxymethamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- metoclopramide intranasal
amoxapine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- midodrine
amoxapine, midodrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- milnacipran
milnacipran and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
- mirtazapine
mirtazapine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- mobocertinib
mobocertinib will decrease the level or effect of amoxapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently
- moxifloxacin
amoxapine and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- nefazodone
nefazodone and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
- netupitant/palonosetron
netupitant/palonosetron, amoxapine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
- nilotinib
amoxapine and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.
- norepinephrine
amoxapine, norepinephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- nortriptyline
amoxapine and nortriptyline both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and nortriptyline both increase serotonin levels. Avoid or Use Alternate Drug. - octreotide
amoxapine and octreotide both increase QTc interval. Avoid or Use Alternate Drug.
- octreotide (Antidote)
amoxapine and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.
- olopatadine intranasal
amoxapine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- ondansetron
amoxapine and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
ondansetron, amoxapine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. - ozanimod
ozanimod increases toxicity of amoxapine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.
- palonosetron
palonosetron, amoxapine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
- paroxetine
paroxetine and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
- perphenazine
perphenazine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- phendimetrazine
amoxapine, phendimetrazine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phentermine
amoxapine, phentermine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phenylephrine
amoxapine, phenylephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phenylephrine PO
amoxapine, phenylephrine PO. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- pirbuterol
amoxapine, pirbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- pitolisant
amoxapine decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.
- promazine
promazine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- propylhexedrine
amoxapine, propylhexedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- protriptyline
amoxapine and protriptyline both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and protriptyline both increase serotonin levels. Avoid or Use Alternate Drug. - pseudoephedrine
amoxapine increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- rasagiline
rasagiline and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
- salmeterol
amoxapine, salmeterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- selegiline transdermal
selegiline transdermal and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
- selinexor
selinexor, amoxapine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
- serdexmethylphenidate/dexmethylphenidate
amoxapine, serdexmethylphenidate/dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- sertraline
sertraline and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
- sodium oxybate
amoxapine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- St John's Wort
amoxapine and St John's Wort both increase serotonin levels. Avoid or Use Alternate Drug.
- tedizolid
tedizolid, amoxapine. Either increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome.
- terbutaline
amoxapine, terbutaline. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- thioridazine
thioridazine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- trazodone
amoxapine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug. - trifluoperazine
trifluoperazine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.
- trimipramine
amoxapine and trimipramine both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug. - umeclidinium bromide/vilanterol inhaled
amoxapine increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
amoxapine and umeclidinium bromide/vilanterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system may be potentiated - vandetanib
amoxapine, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.
- vemurafenib
vemurafenib and amoxapine both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.
- venlafaxine
venlafaxine and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.
- vilanterol/fluticasone furoate inhaled
amoxapine and vilanterol/fluticasone furoate inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system may be potentiated
amoxapine increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated. - vortioxetine
amoxapine, vortioxetine. Either increases effects of the other by serotonin levels. Avoid or Use Alternate Drug.
- xylometazoline
amoxapine, xylometazoline. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- yohimbe
yohimbe, amoxapine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.
- yohimbine
amoxapine, yohimbine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- ziprasidone
amoxapine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.
Monitor Closely (342)
- 5-HTP
amoxapine and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.
- abiraterone
abiraterone increases levels of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.
- abobotulinumtoxinA
abobotulinumtoxinA increases effects of amoxapine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .
- aclidinium
aclidinium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- acrivastine
acrivastine and amoxapine both increase sedation. Use Caution/Monitor.
- albuterol
amoxapine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- alfentanil
alfentanil and amoxapine both increase sedation. Use Caution/Monitor.
- almotriptan
almotriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.
- alprazolam
alprazolam and amoxapine both increase sedation. Use Caution/Monitor.
- amifampridine
amoxapine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.
- amisulpride
amisulpride and amoxapine both increase sedation. Use Caution/Monitor.
- amitriptyline
amitriptyline and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
amitriptyline and amoxapine both increase sedation. Use Caution/Monitor. - amobarbital
amobarbital and amoxapine both increase sedation. Use Caution/Monitor.
- anticholinergic/sedative combos
anticholinergic/sedative combos and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- apomorphine
amoxapine and apomorphine both increase sedation. Use Caution/Monitor.
- arformoterol
amoxapine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- aripiprazole
aripiprazole and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
aripiprazole and amoxapine both increase sedation. Use Caution/Monitor.
aripiprazole and amoxapine both increase QTc interval. Use Caution/Monitor. - armodafinil
amoxapine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- asenapine
asenapine and amoxapine both increase QTc interval. Use Caution/Monitor.
asenapine and amoxapine both increase sedation. Use Caution/Monitor. - asenapine transdermal
asenapine transdermal and amoxapine both increase QTc interval. Use Caution/Monitor.
asenapine transdermal and amoxapine both increase sedation. Use Caution/Monitor. - atazanavir
atazanavir increases levels of amoxapine by unspecified interaction mechanism. Use Caution/Monitor.
- atracurium
atracurium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine
atropine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine IV/IM
atropine IV/IM and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- avapritinib
avapritinib and amoxapine both increase sedation. Use Caution/Monitor.
- azelastine
azelastine and amoxapine both increase sedation. Use Caution/Monitor.
- azithromycin
amoxapine and azithromycin both increase QTc interval. Use Caution/Monitor.
- baclofen
baclofen and amoxapine both increase sedation. Use Caution/Monitor.
- bedaquiline
amoxapine and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely
- belladonna alkaloids
belladonna alkaloids and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- belladonna and opium
belladonna and opium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
belladonna and opium and amoxapine both increase sedation. Use Caution/Monitor. - benperidol
benperidol and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
benperidol and amoxapine both increase sedation. Use Caution/Monitor. - benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen, amoxapine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
benzhydrocodone/acetaminophen and amoxapine both increase sedation. Use Caution/Monitor. - benzphetamine
amoxapine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- benztropine
benztropine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use.
- bethanechol
bethanechol increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- brexpiprazole
brexpiprazole and amoxapine both increase sedation. Use Caution/Monitor.
- brimonidine
brimonidine and amoxapine both increase sedation. Use Caution/Monitor.
- brivaracetam
brivaracetam and amoxapine both increase sedation. Use Caution/Monitor.
- brompheniramine
brompheniramine and amoxapine both increase sedation. Use Caution/Monitor.
- buprenorphine
buprenorphine and amoxapine both increase sedation. Use Caution/Monitor.
- buprenorphine buccal
buprenorphine buccal and amoxapine both increase sedation. Use Caution/Monitor.
- buprenorphine subdermal implant
amoxapine, buprenorphine subdermal implant. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.
buprenorphine subdermal implant and amoxapine both increase sedation. Use Caution/Monitor. - buprenorphine transdermal
buprenorphine transdermal and amoxapine both increase sedation. Use Caution/Monitor.
- buprenorphine, long-acting injection
amoxapine, buprenorphine, long-acting injection. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.
buprenorphine, long-acting injection and amoxapine both increase sedation. Use Caution/Monitor. - bupropion
amoxapine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible.
bupropion will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. - butabarbital
butabarbital and amoxapine both increase sedation. Use Caution/Monitor.
- butalbital
butalbital and amoxapine both increase sedation. Use Caution/Monitor.
- butorphanol
butorphanol and amoxapine both increase sedation. Use Caution/Monitor.
- caffeine
amoxapine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carbachol
carbachol increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carbinoxamine
carbinoxamine and amoxapine both increase sedation. Use Caution/Monitor.
- carisoprodol
carisoprodol and amoxapine both increase sedation. Use Caution/Monitor.
- cenobamate
cenobamate, amoxapine. Either increases effects of the other by sedation. Use Caution/Monitor.
- cevimeline
cevimeline increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- chloral hydrate
chloral hydrate and amoxapine both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
chlordiazepoxide and amoxapine both increase sedation. Use Caution/Monitor.
- chloroquine
chloroquine increases toxicity of amoxapine by QTc interval. Use Caution/Monitor.
- chlorpheniramine
chlorpheniramine and amoxapine both increase sedation. Use Caution/Monitor.
- chlorpromazine
chlorpromazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
chlorpromazine and amoxapine both increase sedation. Use Caution/Monitor. - chlorzoxazone
chlorzoxazone and amoxapine both increase sedation. Use Caution/Monitor.
- cinnarizine
cinnarizine and amoxapine both increase sedation. Use Caution/Monitor.
- cisatracurium
cisatracurium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- citalopram
citalopram and amoxapine both increase QTc interval. Use Caution/Monitor.
- clemastine
clemastine and amoxapine both increase sedation. Use Caution/Monitor.
- clobazam
clobazam will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly.
amoxapine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression). - clomipramine
amoxapine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and clomipramine both increase sedation. Use Caution/Monitor. - clonazepam
clonazepam and amoxapine both increase sedation. Use Caution/Monitor.
- clorazepate
clorazepate and amoxapine both increase sedation. Use Caution/Monitor.
- clozapine
clozapine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
clozapine and amoxapine both increase sedation. Use Caution/Monitor.
clozapine and amoxapine both increase QTc interval. Use Caution/Monitor. - cobicistat
cobicistat will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Carefully titrate antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant response
cobicistat will increase the level or effect of amoxapine by Other (see comment). Use Caution/Monitor. Carefully titrate dose of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitor its response during coadministration with TCAs and cobicistat. - cocaine topical
amoxapine and cocaine topical both increase serotonin levels. Modify Therapy/Monitor Closely.
- codeine
codeine and amoxapine both increase sedation. Use Caution/Monitor.
- crizotinib
crizotinib and amoxapine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
- cyclizine
cyclizine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclizine and amoxapine both increase sedation. Use Caution/Monitor. - cyclobenzaprine
cyclobenzaprine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
cyclobenzaprine and amoxapine both increase sedation. Use Caution/Monitor. - cyproheptadine
cyproheptadine and amoxapine both increase sedation. Use Caution/Monitor.
- dantrolene
dantrolene and amoxapine both increase sedation. Use Caution/Monitor.
- daridorexant
amoxapine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- darifenacin
darifenacin and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- dasatinib
amoxapine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.
- debrisoquine
amoxapine decreases effects of debrisoquine by Other (see comment). Use Caution/Monitor. Comment: Inhibition of uptake by adrenergic neurons.
- desflurane
desflurane and amoxapine both increase sedation. Use Caution/Monitor.
- desipramine
amoxapine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and desipramine both increase sedation. Use Caution/Monitor. - deutetrabenazine
amoxapine and deutetrabenazine both increase sedation. Use Caution/Monitor.
deutetrabenazine and amoxapine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation). - dexchlorpheniramine
dexchlorpheniramine and amoxapine both increase sedation. Use Caution/Monitor.
- dexfenfluramine
amoxapine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
amoxapine and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely. - dexmedetomidine
dexmedetomidine and amoxapine both increase sedation. Use Caution/Monitor.
- dexmethylphenidate
amoxapine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextroamphetamine
amoxapine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
amoxapine and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.
amoxapine increases effects of dextroamphetamine by unknown mechanism. Use Caution/Monitor. - dextroamphetamine transdermal
amoxapine will increase the level or effect of dextroamphetamine transdermal by pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response.
- dextromoramide
dextromoramide and amoxapine both increase sedation. Use Caution/Monitor.
- diamorphine
diamorphine and amoxapine both increase sedation. Use Caution/Monitor.
- diazepam
diazepam and amoxapine both increase sedation. Use Caution/Monitor.
- diazepam intranasal
diazepam intranasal, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- dicyclomine
dicyclomine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- diethylpropion
amoxapine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- difelikefalin
difelikefalin and amoxapine both increase sedation. Use Caution/Monitor.
- difenoxin hcl
difenoxin hcl and amoxapine both increase sedation. Use Caution/Monitor.
- dihydroergotamine
amoxapine and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.
- dihydroergotamine intranasal
amoxapine and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.
- dimenhydrinate
dimenhydrinate and amoxapine both increase sedation. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
diphenhydramine and amoxapine both increase sedation. Use Caution/Monitor. - diphenoxylate hcl
diphenoxylate hcl and amoxapine both increase sedation. Use Caution/Monitor.
- dipipanone
dipipanone and amoxapine both increase sedation. Use Caution/Monitor.
- dobutamine
amoxapine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dofetilide
dofetilide increases toxicity of amoxapine by QTc interval. Use Caution/Monitor.
- dolasetron
amoxapine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.
- donepezil
donepezil increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopamine
amoxapine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopexamine
amoxapine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dosulepin
amoxapine and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and dosulepin both increase sedation. Use Caution/Monitor. - doxepin
amoxapine and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and doxepin both increase sedation. Use Caution/Monitor. - doxylamine
doxylamine and amoxapine both increase sedation. Use Caution/Monitor.
- droperidol
droperidol and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
droperidol and amoxapine both increase sedation. Use Caution/Monitor. - echothiophate iodide
echothiophate iodide increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- eletriptan
eletriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.
- eliglustat
eliglustat increases levels of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.
- elvitegravir/cobicistat/emtricitabine/tenofovir DF
elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.
- ephedrine
amoxapine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
amoxapine increases effects of ephedrine by unknown mechanism. Use Caution/Monitor. - epinephrine
amoxapine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
amoxapine increases effects of epinephrine by unknown mechanism. Use Caution/Monitor. - epinephrine inhaled
amoxapine and epinephrine inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Tricyclic antidepressants may potentiate epinephrine effect on cardiovascular system.
- epinephrine racemic
amoxapine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
amoxapine increases effects of epinephrine racemic by unknown mechanism. Use Caution/Monitor. - ergotamine
amoxapine and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.
- escitalopram
escitalopram increases toxicity of amoxapine by QTc interval. Use Caution/Monitor.
- esketamine intranasal
esketamine intranasal, amoxapine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- estazolam
estazolam and amoxapine both increase sedation. Use Caution/Monitor.
- ethanol
amoxapine and ethanol both increase sedation. Use Caution/Monitor.
- etomidate
etomidate and amoxapine both increase sedation. Use Caution/Monitor.
- ezogabine
ezogabine, amoxapine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.
- fedratinib
fedratinib will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.
- fenfluramine
amoxapine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
amoxapine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.
fenfluramine, amoxapine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome. - fesoterodine
fesoterodine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- flavoxate
flavoxate and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- flecainide
amoxapine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.
- fluoxetine
amoxapine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.
- fluphenazine
fluphenazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
fluphenazine and amoxapine both increase sedation. Use Caution/Monitor. - flurazepam
flurazepam and amoxapine both increase sedation. Use Caution/Monitor.
- fluvoxamine
fluvoxamine and amoxapine both increase QTc interval. Modify Therapy/Monitor Closely.
- formoterol
amoxapine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- foscarnet
amoxapine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.
- frovatriptan
frovatriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.
- gabapentin
gabapentin, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- gabapentin enacarbil
gabapentin enacarbil, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- galantamine
galantamine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ganaxolone
amoxapine and ganaxolone both increase sedation. Use Caution/Monitor.
- glycopyrrolate
glycopyrrolate and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor. - glycopyrrolate inhaled
glycopyrrolate inhaled and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine increases levels of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor. - glycopyrronium tosylate topical
glycopyrronium tosylate topical, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.
- haloperidol
haloperidol and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
haloperidol and amoxapine both increase sedation. Use Caution/Monitor. - henbane
henbane and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- homatropine
homatropine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- huperzine A
huperzine A increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- hydrocodone
hydrocodone, amoxapine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
- hydromorphone
hydromorphone and amoxapine both increase sedation. Use Caution/Monitor.
- hydroxyzine
hydroxyzine and amoxapine both increase sedation. Use Caution/Monitor.
- hyoscyamine
hyoscyamine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- hyoscyamine spray
hyoscyamine spray and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- iloperidone
iloperidone and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
amoxapine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.
iloperidone and amoxapine both increase sedation. Use Caution/Monitor. - imipramine
amoxapine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and imipramine both increase sedation. Use Caution/Monitor. - indacaterol, inhaled
indacaterol, inhaled, amoxapine. QTc interval. Use Caution/Monitor. Indacaterol should be administered with extreme caution to patients treated with TCAs. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.
- ioflupane I 123
amoxapine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I123 administration.
- ipratropium
ipratropium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- isoniazid
amoxapine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.
- isoproterenol
amoxapine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ketamine
ketamine and amoxapine both increase sedation. Use Caution/Monitor.
- ketotifen, ophthalmic
amoxapine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- L-tryptophan
amoxapine and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.
- lapatinib
amoxapine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.
- lasmiditan
lasmiditan, amoxapine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
amoxapine increases effects of lasmiditan by serotonin levels. Use Caution/Monitor. Coadministration may increase risk of serotonin syndrome. - lemborexant
lemborexant, amoxapine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- levalbuterol
amoxapine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- levofloxacin
amoxapine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- levorphanol
levorphanol and amoxapine both increase sedation. Use Caution/Monitor.
- levothyroxine
levothyroxine increases effects of amoxapine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.
- liothyronine
liothyronine increases effects of amoxapine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.
- liotrix
liotrix increases effects of amoxapine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.
- lisdexamfetamine
amoxapine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
amoxapine, lisdexamfetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s). - lithium
amoxapine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.
- lofepramine
amoxapine and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and lofepramine both increase sedation. Use Caution/Monitor. - lofexidine
amoxapine and lofexidine both increase sedation. Use Caution/Monitor.
amoxapine decreases effects of lofexidine by unspecified interaction mechanism. Use Caution/Monitor. - loprazolam
loprazolam and amoxapine both increase sedation. Use Caution/Monitor.
- lorazepam
lorazepam and amoxapine both increase sedation. Use Caution/Monitor.
- lorcaserin
lorcaserin will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- lormetazepam
lormetazepam and amoxapine both increase sedation. Use Caution/Monitor.
- loxapine
loxapine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
loxapine and amoxapine both increase sedation. Use Caution/Monitor. - loxapine inhaled
loxapine inhaled and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
loxapine inhaled and amoxapine both increase sedation. Use Caution/Monitor. - lsd
amoxapine and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.
- lurasidone
amoxapine, lurasidone. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS effects .
lurasidone and amoxapine both increase pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS effects - maprotiline
amoxapine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and maprotiline both increase sedation. Use Caution/Monitor. - maraviroc
maraviroc, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.
- marijuana
amoxapine and marijuana both increase sedation. Use Caution/Monitor.
- meclizine
meclizine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- melatonin
amoxapine and melatonin both increase sedation. Use Caution/Monitor.
- meperidine
meperidine and amoxapine both increase sedation. Use Caution/Monitor.
- meprobamate
amoxapine and meprobamate both increase sedation. Use Caution/Monitor.
- metaproterenol
amoxapine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaxalone
metaxalone and amoxapine both increase sedation. Use Caution/Monitor.
- methadone
amoxapine and methadone both increase QTc interval. Modify Therapy/Monitor Closely.
methadone and amoxapine both increase sedation. Use Caution/Monitor. - methamphetamine
amoxapine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methocarbamol
methocarbamol and amoxapine both increase sedation. Use Caution/Monitor.
- methscopolamine
methscopolamine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- methylenedioxymethamphetamine
amoxapine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methylphenidate
amoxapine, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- methylphenidate transdermal
methylphenidate transdermal will increase the level or effect of amoxapine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate.
- metoclopramide
amoxapine and metoclopramide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
metoclopramide and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. - midazolam
midazolam and amoxapine both increase sedation. Use Caution/Monitor.
- midazolam intranasal
midazolam intranasal, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- midodrine
amoxapine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mifepristone
mifepristone, amoxapine. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.
- mirabegron
mirabegron will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- mirtazapine
amoxapine and mirtazapine both increase sedation. Use Caution/Monitor.
amoxapine and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely. - modafinil
amoxapine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- morphine
morphine and amoxapine both increase sedation. Use Caution/Monitor.
amoxapine and morphine both increase serotonin levels. Modify Therapy/Monitor Closely. - motherwort
amoxapine and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
amoxapine and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
amoxapine and nabilone both increase sedation. Use Caution/Monitor.
- nalbuphine
nalbuphine and amoxapine both increase sedation. Use Caution/Monitor.
- naratriptan
naratriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.
- nefopam
nefopam, amoxapine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Use combination with caution.
- neostigmine
neostigmine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- norepinephrine
amoxapine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
amoxapine increases effects of norepinephrine by unknown mechanism. Use Caution/Monitor. - nortriptyline
amoxapine and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and nortriptyline both increase sedation. Use Caution/Monitor. - ofloxacin
amoxapine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- olanzapine
olanzapine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
olanzapine and amoxapine both increase sedation. Use Caution/Monitor.
olanzapine and amoxapine both increase QTc interval. Use Caution/Monitor. - oliceridine
amoxapine, oliceridine. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely.
amoxapine increases toxicity of oliceridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics. - olodaterol inhaled
amoxapine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias
- onabotulinumtoxinA
onabotulinumtoxinA and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- opium tincture
opium tincture and amoxapine both increase sedation. Use Caution/Monitor.
- orphenadrine
amoxapine and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.
orphenadrine and amoxapine both increase sedation. Use Caution/Monitor. - osimertinib
osimertinib and amoxapine both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.
- oxaliplatin
oxaliplatin will increase the level or effect of amoxapine by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
- oxazepam
oxazepam and amoxapine both increase sedation. Use Caution/Monitor.
- oxybutynin
oxybutynin and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin topical
oxybutynin topical and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin transdermal
oxybutynin transdermal and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxycodone
oxycodone and amoxapine both increase sedation. Use Caution/Monitor.
- oxymetazoline intranasal
amoxapine increases effects of oxymetazoline intranasal by pharmacodynamic synergism. Use Caution/Monitor. TCAs inhibit norepinephrine uptake in adrenergic neurons, thereby increasing synaptic norepinephrine levels. Coadministration with alpha1 agonists may cause increased adrenergic receptor stimulation. When oxymetazoline is combined with intranasal tetracaine for dental anesthesia, avoid or use alternant anesthetic in patients taking TCAs.
- oxymorphone
oxymorphone and amoxapine both increase sedation. Use Caution/Monitor.
- ozanimod
ozanimod and amoxapine both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.
- paliperidone
paliperidone and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
amoxapine and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.
paliperidone and amoxapine both increase sedation. Use Caution/Monitor. - pancuronium
pancuronium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- papaveretum
papaveretum and amoxapine both increase sedation. Use Caution/Monitor.
- papaverine
amoxapine and papaverine both increase sedation. Use Caution/Monitor.
- paroxetine
amoxapine and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.
- pasireotide
amoxapine and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.
- pazopanib
amoxapine and pazopanib both increase QTc interval. Use Caution/Monitor.
- peginterferon alfa 2b
peginterferon alfa 2b, amoxapine. Other (see comment). Use Caution/Monitor. Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.
- pentazocine
pentazocine and amoxapine both increase sedation. Use Caution/Monitor.
amoxapine and pentazocine both increase serotonin levels. Modify Therapy/Monitor Closely. - pentobarbital
pentobarbital and amoxapine both increase sedation. Use Caution/Monitor.
- perphenazine
perphenazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
perphenazine and amoxapine both increase sedation. Use Caution/Monitor. - phendimetrazine
amoxapine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenobarbital
phenobarbital and amoxapine both increase sedation. Use Caution/Monitor.
- phentermine
amoxapine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine
amoxapine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine ophthalmic
amoxapine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phenylephrine PO
amoxapine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pholcodine
amoxapine and pholcodine both increase sedation. Use Caution/Monitor.
- physostigmine
physostigmine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pilocarpine
pilocarpine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pimozide
pimozide and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
pimozide and amoxapine both increase sedation. Use Caution/Monitor. - pirbuterol
amoxapine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- posaconazole
amoxapine and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- pralidoxime
pralidoxime and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- pregabalin
pregabalin, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- primidone
primidone and amoxapine both increase sedation. Use Caution/Monitor.
- prochlorperazine
prochlorperazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
prochlorperazine and amoxapine both increase QTc interval. Use Caution/Monitor.
prochlorperazine and amoxapine both increase sedation. Use Caution/Monitor. - promethazine
promethazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
promethazine and amoxapine both increase QTc interval. Use Caution/Monitor.
promethazine and amoxapine both increase sedation. Use Caution/Monitor. - propantheline
propantheline and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- propofol
propofol and amoxapine both increase sedation. Use Caution/Monitor.
- propylhexedrine
amoxapine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- protriptyline
amoxapine and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and protriptyline both increase sedation. Use Caution/Monitor. - pyridostigmine
pyridostigmine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- quazepam
quazepam and amoxapine both increase sedation. Use Caution/Monitor.
- quetiapine
quetiapine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
quetiapine and amoxapine both increase sedation. Use Caution/Monitor.
quetiapine, amoxapine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT. - quinine
amoxapine and quinine both increase QTc interval. Use Caution/Monitor.
- ramelteon
amoxapine and ramelteon both increase sedation. Use Caution/Monitor.
- ranolazine
amoxapine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.
- rapacuronium
rapacuronium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- remimazolam
remimazolam, amoxapine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
- rifabutin
rifabutin decreases levels of amoxapine by increasing metabolism. Use Caution/Monitor.
- rilpivirine
rilpivirine increases toxicity of amoxapine by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.
- risperidone
amoxapine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.
risperidone and amoxapine both increase sedation. Use Caution/Monitor. - rizatriptan
rizatriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.
- rocuronium
rocuronium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- rolapitant
rolapitant will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration.
- romidepsin
amoxapine and romidepsin both increase QTc interval. Modify Therapy/Monitor Closely.
- salmeterol
amoxapine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- SAMe
amoxapine and SAMe both increase serotonin levels. Modify Therapy/Monitor Closely.
- scopolamine
scopolamine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- scullcap
amoxapine and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
secobarbital and amoxapine both increase sedation. Use Caution/Monitor.
- selpercatinib
selpercatinib increases toxicity of amoxapine by QTc interval. Use Caution/Monitor.
- sertraline
sertraline and amoxapine both increase QTc interval. Use Caution/Monitor.
- shepherd's purse
amoxapine and shepherd's purse both increase sedation. Use Caution/Monitor.
- sodium sulfate/?magnesium sulfate/potassium chloride
sodium sulfate/?magnesium sulfate/potassium chloride increases effects of amoxapine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.
- sodium sulfate/potassium sulfate/magnesium sulfate
sodium sulfate/potassium sulfate/magnesium sulfate increases effects of amoxapine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.
- sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol
amoxapine, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.
- solifenacin
solifenacin and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
solifenacin and amoxapine both increase QTc interval. Use Caution/Monitor. - sorafenib
sorafenib and amoxapine both increase QTc interval. Use Caution/Monitor.
- stiripentol
stiripentol, amoxapine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.
- succinylcholine
succinylcholine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- sufentanil
sufentanil and amoxapine both increase sedation. Use Caution/Monitor.
- sufentanil SL
sufentanil SL, amoxapine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
- sulfamethoxazole
amoxapine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- sumatriptan
sumatriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.
- sumatriptan intranasal
sumatriptan intranasal and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.
- suvorexant
suvorexant and amoxapine both increase sedation. Modify Therapy/Monitor Closely. Dosage adjustments of suvorexant and concomitant CNS depressants may be necessary
- tapentadol
tapentadol and amoxapine both increase sedation. Use Caution/Monitor.
amoxapine and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely. - telavancin
amoxapine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- temazepam
temazepam and amoxapine both increase sedation. Use Caution/Monitor.
- terbinafine
terbinafine will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug.
- terbutaline
amoxapine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- tetrabenazine
amoxapine and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
- thioridazine
thioridazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
thioridazine and amoxapine both increase sedation. Use Caution/Monitor. - thiothixene
thiothixene and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.
thiothixene and amoxapine both increase sedation. Use Caution/Monitor. - thyroid desiccated
thyroid desiccated increases effects of amoxapine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.
- tiotropium
tiotropium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- tolterodine
tolterodine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- topiramate
amoxapine and topiramate both increase sedation. Modify Therapy/Monitor Closely.
- tramadol
tramadol and amoxapine both increase sedation. Use Caution/Monitor.
amoxapine and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely. - trazodone
amoxapine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and trazodone both increase sedation. Use Caution/Monitor. - triazolam
triazolam and amoxapine both increase sedation. Use Caution/Monitor.
- triclofos
triclofos and amoxapine both increase sedation. Use Caution/Monitor.
- trifluoperazine
trifluoperazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.
trifluoperazine and amoxapine both increase sedation. Use Caution/Monitor. - trihexyphenidyl
trihexyphenidyl and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.
- trimethoprim
amoxapine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.
- trimipramine
amoxapine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and trimipramine both increase sedation. Use Caution/Monitor. - triprolidine
triprolidine and amoxapine both increase sedation. Use Caution/Monitor.
- tropisetron
amoxapine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.
- trospium chloride
trospium chloride and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- valbenazine
valbenazine and amoxapine both increase QTc interval. Use Caution/Monitor.
- valerian
valerian and amoxapine both increase sedation. Use Caution/Monitor.
- vecuronium
vecuronium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- venlafaxine
amoxapine and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.
- voclosporin
voclosporin, amoxapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.
- voriconazole
amoxapine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- xylometazoline
amoxapine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- yohimbine
amoxapine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziconotide
amoxapine and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
ziprasidone and amoxapine both increase sedation. Use Caution/Monitor.
- zolmitriptan
zolmitriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.
Minor (71)
- acarbose
amoxapine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.
- amobarbital
amobarbital, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- atropine
amoxapine increases levels of atropine by unknown mechanism. Minor/Significance Unknown.
- atropine IV/IM
amoxapine increases levels of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.
- bazedoxifene/conjugated estrogens
bazedoxifene/conjugated estrogens, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- brimonidine
amoxapine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- butabarbital
butabarbital, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- butalbital
butalbital, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- carbamazepine
carbamazepine decreases levels of amoxapine by increasing metabolism. Minor/Significance Unknown.
- chlorpromazine
amoxapine, chlorpromazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
amoxapine, chlorpromazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - chlorpropamide
amoxapine increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.
- conjugated estrogens
conjugated estrogens, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- conjugated estrogens, vaginal
conjugated estrogens, vaginal, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- desflurane
desflurane, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- dexmethylphenidate
dexmethylphenidate increases effects of amoxapine by decreasing metabolism. Minor/Significance Unknown.
- estradiol
estradiol, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- estrogens conjugated synthetic
estrogens conjugated synthetic, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- estrogens esterified
estrogens esterified, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens may inhibit hepatic metabolism of tricyclic antidepressants. However, interactions are not common.
- estropipate
estropipate, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- ethinylestradiol
ethinylestradiol, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- etomidate
etomidate, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- eucalyptus
amoxapine and eucalyptus both increase sedation. Minor/Significance Unknown.
- fluphenazine
amoxapine, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
amoxapine, fluphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
fluphenazine, amoxapine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - glimepiride
amoxapine increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.
- glipizide
amoxapine increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.
- glyburide
amoxapine increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.
- hydroxyprogesterone caproate (DSC)
hydroxyprogesterone caproate (DSC), amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- insulin aspart
amoxapine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin detemir
amoxapine increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin glargine
amoxapine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin glulisine
amoxapine increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin lispro
amoxapine increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin NPH
amoxapine increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin regular human
amoxapine increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.
- isoproterenol
isoproterenol, amoxapine. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.
- ketamine
ketamine, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- lithium
lithium, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved.
- mestranol
mestranol, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- metformin
amoxapine increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.
- miglitol
amoxapine increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.
- nateglinide
amoxapine increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.
- panax ginseng
panax ginseng increases effects of amoxapine by pharmacodynamic synergism. Minor/Significance Unknown.
- pentobarbital
pentobarbital, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- perphenazine
amoxapine, perphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
amoxapine, perphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - phenobarbital
phenobarbital, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- pioglitazone
amoxapine increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
- pleurisy root
pleurisy root decreases effects of amoxapine by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.
- primidone
primidone, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- prochlorperazine
amoxapine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
amoxapine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - progesterone micronized
progesterone micronized, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- promazine
amoxapine, promazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
amoxapine, promazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - promethazine
amoxapine, promethazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
amoxapine, promethazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
promethazine, amoxapine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - propofol
propofol, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- repaglinide
amoxapine increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.
- risperidone
risperidone and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Minor/Significance Unknown.
- rosiglitazone
amoxapine increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
- sage
amoxapine and sage both increase sedation. Minor/Significance Unknown.
- saxagliptin
amoxapine increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
- secobarbital
secobarbital, amoxapine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- serdexmethylphenidate/dexmethylphenidate
serdexmethylphenidate/dexmethylphenidate increases effects of amoxapine by decreasing metabolism. Minor/Significance Unknown.
- sevoflurane
sevoflurane, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- sitagliptin
amoxapine increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
- sulfamethoxazole
sulfamethoxazole decreases levels of amoxapine by unspecified interaction mechanism. Minor/Significance Unknown.
- thioridazine
amoxapine, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
amoxapine, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - tolazamide
amoxapine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.
- tolbutamide
amoxapine increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.
- trifluoperazine
amoxapine, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
amoxapine, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - vasopressin
amoxapine increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.
- verapamil
verapamil increases levels of amoxapine by decreasing metabolism. Minor/Significance Unknown.
- vildagliptin
amoxapine increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
- zolpidem
zolpidem, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.
Adverse Effects
>10%
Constipation (12-14%)
Dry mouth (12-14%)
Sedation (12-14%)
1-10%
Anxiety
Ataxia
Blurred vision
Confusion
Dizziness
Edema
Headache
Fatigue
Nausea
Nervousness/restlessness
Prolactin levels increased
Rash
Sweating
Tremor
Weakness
<1%
Agranulocytosis
Diarrhea
ECG changes
EPS
Flatulence
Galactorrhea
Hypertension
Leukopenia
Menstrual irregularity
Mydriasis
Orthostatic hypotension
Seizure
Urinary retention
Urticaria
Vomiting
Tachycardia
Sexual dysfunction
Frequency Not Defined
neuroleptic malignant syndrome (rare)
Warnings
Black Box Warnings
In short-term studies, antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (<24 yr of age) taking antidepressants for major depressive disorders and other psychiatric illnesses
This increase was not seen in patients aged >24 years; a slight decrease in suicidal thinking was seen in adults >65 years
In children and young adults, risks must be weighed against the benefits of taking antidepressants
Patients should be monitored closely for changes in behavior, clinical worsening, and suicidal tendencies; this should be done during initial 1-2 months of therapy and dosage adjustments
The patient’s family should communicate any abrupt changes in behavior to the healthcare provider
Worsening behavior and suicidal tendencies that are not part of the presenting symptoms may require discontinuation of therapy
This drug is not approved for use in pediatric patients
Contraindications
Hypersensitivity
Severe cardiovascular d/o
Uncorrected narrow angle glaucoma
Within 14 day of MAOIs (risk of serotonin syndrome); if linezolid or IV methylene blue (MAOIs) must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity; may resume 24 hr after last linezolid or methylene blue dose, or after 2 weeks of monitoring, whichever comes first
Any drugs or conditions that prolong QT interval
Acute recovery post-MI
Cautions
BPH, urinary/GI retention, incr IOP, hyperthyroidism, opne angle glaucoma, seizure d/o, brain tumor, respiratory impairment, hyperthyroidism
Clinical worsening & suicide ideation may occur despite medication in adolescents & young adults (18-24 yo)
Risk of anticholinergic side effects
Possibility of tardive dyskinesia & NMS
Pregnancy & Lactation
Pregnancy Category: C
Lactation: enters breast milk; use with caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Neurotransmitter (esp NE & serotonin) reuptake inhibitor; anticholinergic
Pharmacokinetics
Half-Life: 8-30 hr
Peak Plasma Time: 90 min
Bioavailability: Almost complete absorption
Metabolites: 8-hydroxyamoxapine
Vd: 0.9-1.2 L/kg
Protein binding: 90%
Excretion: Urine (60%); Feces: (18%)
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
amoxapine oral - | 150 mg tablet | ![]() | |
amoxapine oral - | 100 mg tablet | ![]() | |
amoxapine oral - | 50 mg tablet | ![]() | |
amoxapine oral - | 25 mg tablet | ![]() |
Copyright © 2010 First DataBank, Inc.
Patient Handout
amoxapine oral
AMOXAPINE - ORAL
(a-MOX-a-peen)
COMMON BRAND NAME(S): Asendin
WARNING: Antidepressant medications are used to treat a variety of conditions, including depression and other mental/mood disorders. These medications can help prevent suicidal thoughts/attempts and provide other important benefits. However, studies have shown that a small number of people (especially people younger than 25) who take antidepressants for any condition may experience worsening depression, other mental/mood symptoms, or suicidal thoughts/attempts. It is very important to talk with the doctor about the risks and benefits of antidepressant medication (especially for people younger than 25), even if treatment is not for a mental/mood condition.Tell the doctor right away if you notice worsening depression/other psychiatric conditions, unusual behavior changes (including possible suicidal thoughts/attempts), or other mental/mood changes (including new/worsening anxiety, panic attacks, trouble sleeping, irritability, hostile/angry feelings, impulsive actions, severe restlessness, very rapid speech). Be especially watchful for these symptoms when a new antidepressant is started or when the dose is changed.
USES: This medication is used to treat depression. Treating depression can improve your mood and sense of well-being and allow you to enjoy everyday life more.Amoxapine is a tricyclic antidepressant. It works by restoring the balance of natural chemicals (neurotransmitters) in the brain. Because amoxapine has some effects that are similar to those of major tranquilizers, it may work better in patients who have agitation or anxiety along with depression.
HOW TO USE: Read the Medication Guide provided by your pharmacist before you start taking amoxapine and each time you get a refill. If you have any questions, ask your doctor or pharmacist.Take this medication by mouth with or without food as directed by your doctor, usually 1 to 3 times daily. To lessen side effects, amoxapine may be started at a low dose and slowly increased as your body gets used to it. Follow your doctor's instructions carefully. If you are taking this medication once daily, it is usually taken at bedtime to prevent daytime drowsiness. The dosage is based on your medical condition, age, and response to treatment.Use this medication regularly in order to get the most benefit from it. To help you remember, use it at the same time(s) each day. This medication does not work right away. It may take up to two weeks before you experience the full benefits.Keep taking this medication even if you feel well. Do not suddenly stop taking this medication without consulting your doctor. Some conditions may become worse when the drug is abruptly stopped. Your dose may need to be gradually decreased.Inform your doctor if your condition does not improve or if it worsens.
SIDE EFFECTS: See also the Warning section.Drowsiness, dizziness, difficulty urinating, dry mouth, constipation, headache, weakness, blurred vision, or changes in appetite/weight may occur as your body gets used to the medication. If any of these effects last or get worse, tell your doctor or pharmacist promptly.To relieve dry mouth, suck on (sugarless) hard candy or ice chips, chew (sugarless) gum, drink water or use a saliva substitute. If any of these effects last or get worse, notify your doctor or pharmacist promptly.To prevent constipation, eat dietary fiber, drink enough water, and exercise. You may also need to take a laxative. Ask your pharmacist which type of laxative is right for you.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: fainting, mental/mood changes (such as confusion, depression, hallucinations, nervousness, restlessness), numbness/tingling of the hands/feet, ringing in the ears, shakiness (tremors), stomach/abdominal pain, severe vomiting/constipation.Get medical help right away if you have any very serious side effects, including: chest/jaw/left arm pain, slow/fast/irregular heartbeat, pain/redness/swelling of arms/legs, seizures, severe headache, weakness on one side of the body, eye pain/swelling/redness, widened pupils, vision changes (such as seeing rainbows around lights at night), trouble speaking.In rare instances, this medication may increase your level of a certain natural chemical made by the body (prolactin). For females, this increase in prolactin may result in unwanted breast milk, missing/stopped periods, or difficulty becoming pregnant. For males, it may result in decreased sexual ability, inability to produce sperm, or enlarged breasts. If you develop any of these symptoms, tell your doctor right away.This drug may rarely cause a condition known as tardive dyskinesia. In some cases, this condition may be permanent. Tell your doctor right away if you develop any unusual/uncontrolled movements (especially of the face, mouth, tongue, arms or legs).Amoxapine may rarely cause a serious condition called neuroleptic malignant syndrome. Get medical help right away if you develop the following: fever, muscle stiffness, increased sweating, fast/irregular heartbeat, severe confusion.This medication may rarely cause serious blood problems (such as agranulocytosis, thrombocytopenia) or liver problems. Get medical help right away if you notice any of the following very serious side effects: easy bleeding/bruising, signs of infection (such as sore throat that doesn't go away, fever), severe stomach/abdominal pain, dark urine, yellowing of the eyes/skin.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: See also the Warning section.Before taking amoxapine, tell your doctor or pharmacist if you are allergic to it; or to other tricyclic antidepressants (such as amitriptyline); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: blood problems (such as agranulocytosis, thrombocytopenia), breathing problems (such as asthma, COPD), personal or family history of glaucoma (angle-closure type), intestinal problems (such as chronic constipation, ileus), heart problems (such as recent heart attack, arrhythmias, coronary artery disease, heart failure), kidney problems, liver problems, other mental/mood conditions (such as bipolar disorder, psychosis), family history of mental/mood conditions (such as bipolar disorder) or suicide, history of neuroleptic malignant syndrome, movement disorders (such as Parkinson's disease, tardive dyskinesia), overactive thyroid (hyperthyroidism), problems urinating (urinary retention, enlarged prostate), seizures, conditions that may increase your risk of seizures (such as electroshock therapy, stroke, alcohol withdrawal).This drug may make you dizzy or drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).To minimize the dizziness and lightheadedness, get up slowly when rising from a seated or lying position.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).This medication may make you more sensitive to the sun. Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. Tell your doctor right away if you get sunburned or have skin blisters/redness.Older adults may be more sensitive to the side effects of this drug, especially drowsiness, dizziness, confusion, constipation, trouble urinating, and involuntary movements (tardive dyskinesia). Drowsiness, dizziness, and confusion can increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Infants born to mothers who have taken similar medications during pregnancy may have problems such as very deep sleep, trouble urinating, shaking (tremors), and seizures. Discuss the risks and benefits with your doctor.Since untreated mental/mood problems (such as depression, panic disorders, bipolar disorder) can be a serious condition, do not stop taking this medication unless directed by your doctor. If you are planning pregnancy, become pregnant, or think you may be pregnant, immediately discuss with your doctor the benefits and risks of using this medication during pregnancy.This medication passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: anticholinergics (such as atropine, belladonna alkaloids), certain drugs for high blood pressure (such as clonidine, guanethidine), drugs for motion sickness (such as meclizine), psychiatric drugs (such as antipsychotics, antidepressants), thyroid supplements.Taking MAO inhibitors with this medication may cause a serious (possibly fatal) drug interaction. Avoid taking MAO inhibitors (isocarboxazid, linezolid, metaxalone, methylene blue, moclobemide, phenelzine, procarbazine, rasagiline, safinamide, selegiline, tranylcypromine) during treatment with this medication. Most MAO inhibitors should also not be taken for two weeks before treatment with this medication. Ask your doctor when to start or stop taking this medication.Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), muscle relaxants (such as carisoprodol, cyclobenzaprine), or antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.This medication may interfere with certain medical/lab tests (such as brain scan for Parkinson's disease), possibly causing false test results. Make sure lab personnel and all your doctors know you use this drug.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Overdose of this medication may be fatal and symptoms include: seizures, delirium, and loss of consciousness .
NOTES: Do not share this medication with others.Lab and/or medical tests may be done while you are taking this medication. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised May 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.